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Abstract: Meningioma is among the most frequent brain 
tumours predominantly affecting elderly women. Epide-
miological studies have shown that at the age of fertility 
the incidence is relatively low. The biological behaviour of 
meningioma in pregnancy is different from other menin-
giomas. The possible explanation is rooted in the complex 
physiological changes and hormonal differences during 
pregnancy. The increased meningioma growth observed 
in pregnancy is presumably the result of endocrine mech-
anisms. These include increase in progesterone, human 
placental lactogen (hPL) and prolactin (PRL) serum 
levels. In contrast, levels of pituitary hormones such as 
follicle stimulating hormone (FSH), luteinizing hormone 
(LH) and human chorionic gonadotropin (hCG) produced 
by the placenta are decreasing in the mother prior to 
childbirth. Besides, vascular factors also play a crucial 
role. Peritumoral brain edema (PTBE), with well-known 
causative association with vascular endothelial growth 
factor (VEGF), can often be seen both with imaging and 
in the surgical specimens. Our aim is to assess published 
research on this topic including diagnostic and therapeu-
tic guidelines, and to provide a clinically useful overview 
on the pathophysiology and biological behaviour of this 
rare complication of pregnancy. 
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1  Introduction
Meningiomas are responsible for more than one third of all 
intracranial tumours. They are more frequent in women, 
the ratio of female to male is 3:2. Primarily the elderly aged 
60 -70 are affected. Meningioma has been first described 
by Harvey Cushing in 1922 and he was the first to name 
these tumours meningiomas [1]. Despite the high inci-
dence of meningioma, the pathophysiology has not been 
fully understood [2]. Regarding genetic background, men-
ingiomas could be a part of a familial tumour syndrome, 
most frequently associated with Neurofibromatosis type 2 
(NF2) with NF2 gene mutation [3]. The gene is coding the 
tumour suppressor protein merlin, which has mutations 
in up to 60% of sporadic cases [4]. With recent advance of 
genetic research, the epigenetic background of meningi-
oma pathogenesis has been elucidated in some details [5]. 
The aberrant DNA methylation affects numerous promot-
ers and homeobox genes in meningiomas. Although, the 
role of histone modification has not been proven, changes 
in microRNAs regulating post translational silencing 
increase the chance of recurrence. Important environmen-
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tal factor is the irradiation on the head and neck region. 
Meningiomas are frequent in survivors of nuclear disas-
ters and there is an increased incidence of these tumours 
in patients who have had iatrogenic diagnostic or ther-
apeutic irradiation [6]. With the increasing use of tele-
communication technologies, including mobile phones, 
an association between meningioma pathogenesis and 
electromagnetic wave has been suggested. Although no 
significant and proven relationship has been established 
between the use of cell phones and meningioma develop-
ment, it should be taken account that in these studies the 
follow-up time is relatively short [7]. Head injury has also 
been proposed and in some studies proven as a causative 
factor for meningioma development [8]. A comprehen-
sive epidemiological study has established relationship 
between smoking and occupational exposure to heavy 
metals. In contrast, food rich in fresh vegetables and fruit 
appears to be protective [9]. There has been no statisti-
cally proven link between alcohol consumption and car-
cinogenesis [10]. The diagnosis of meningioma requires 
imaging techniques, either Computed Tomography (CT) or 
Magnetic Resonance Imaging (MRI). There are character-
istic imaging features, dural tail, peritumoral brain edema 
(PTBE) and calcification on CT which are important addi-
tional clues to establish the diagnosis [11]. Clinical signs 
during tumour growth are caused by the space occupying 
and compressive effect of the tumours upon the under-
lying central nervous system structures. Therefore, even 
histologically benign tumours could prove clinically unfa-
vourable or even lethal. Histological grading of tumour 
is based on the most recent World Health Organization 
Classification of Tumors of the Central Nervous System 
classification of meningioma (2016) [12]. Within the three 
grades (WHO grade I, II, III) 15 histological subtypes 
can be differentiated. WHO grade I tumours are menin-
gothelial, microcystic, fibrous, secretory, transitional, 
lymphoplasmacyte-rich, psammomatous, metaplastic 
and angiomatous. WHO grade II tumours are chordoid, 
clear cell and atypical meningiomas with the presence of 
brain invasion, while WHO grade III tumours are papil-
lary, rhabdoid and anaplastic meningiomas (irrespective 
of brain invasion). The WHO grade has a very important 
and comparatively accurate prognostic role. The chance 
of meningioma recurrence in WHO grade I, II, III ranges 
between 7-25%; 29-52%; 53-94% respectively. Beside the 
most frequent types there are rare meningioma variants; 
as an example, we refer to our case report of a 72-years 
old woman [13]. For better understanding the pathophys-
iology and risk of recurrence, simple neuropathological 
diagnostic methods like immunohistochemistry can be 
helpful. Such studies shed light to prognostic protein 
markers involved in carcinogenesis and progression [14]. 
The analysis of invasion-related molecules has revealed 
important findings regarding recurrence in malignant 
gliomas [14-15], which might be implicated also in men-
ingiomas, although the infiltrative potential in gliomas is 
characteristically much higher. Certainly, meningiomas 
are far less invasive tumours; nevertheless, the analysis 
of factors implicated in invasive growth and therefore 
increased risk of recurrence could improve our under-
standing of the underlying pathophysiology of meningi-
oma recurrence. 
Meningiomas rarely develop over the course of preg-
nancy. It is estimated that there are 5,6 cases out of 100.000 
pregnancies [16]. One of the reasons for the low incidence 
is the fact that the range of fertility is approximately 15-45 
years of age and during this time tumours in general are 
relatively low in frequency. This is also true for meningi-
omas, which have highest incidence between the ages of 
60 and 70. The first literature report on a brain tumour in 
a pregnant woman was published by Barnard in 1898 [17]. 
A case report by Cushing and Eisenhardt on a pregnant 
woman with parasellar meningioma was issued in 1929. 
They reported rapid progression of visual impairment, 
which appeared reversible post-partum and recurred in 
the next pregnancy [18]. One important aspect of menin-
gioma in pregnancy is the potentially rapid growth with 
life-threatening complications [19]. Owing to its localisa-
tion it can have a distribution similar to meningioma in 
the non-pregnant population. Meningiomas close to the 
skull base have special clinical relevance because they 
cause severe complications more frequently with the 
increased intracranial pressure [20]. In such cases the ini-
tiation of the adequate or available therapy is mandatory 
because a delay could cause life-threatening complication 
both to the foetus and the mother. The primary goal of the 
therapy is to save lives, which requires the close collabo-
ration of the neurosurgeon, gynaecologist and the anaes-
thesiologist [21]. 
2  Pathophysiological and morpho-
logical aspects
During pregnancy there are several physiological changes 
in the mother’s body with the primary aim to support 
the foetus’s growth and to enable the normal progres-
sion of pregnancy and childbirth. In this adaptive envi-
ronment of pregnancy a pathological process such as 
brain tumour can present with very different character-
istics and biological behaviour. The background of the 
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complex pathophysiological and morphological changes 
in tumours in pregnancy are far from being understood. In 
the following deep review of the literature, there are two 
cardinal mechanisms to be considered: endocrine and 
vascular.
2.1  Endocrinological considerations
It has been shown that meningioma growth is enhanced 
in the progesterone-dominated luteal phase of the men-
strual cycle [22]. Following successful conception, within 
the first four weeks, the estrogen and progesterone secre-
tion becomes limited exclusively to the ovary. In this 
process the hCG produced by syncytiotrophoblasts is 
indispensable for maintaining the corpus luteum, there-
fore hCG plays its key role in the first twenty weeks of 
pregnancy. However, from week ten onwards the placenta 
takes over the production of estrogen and progesterone. 
During pregnancy, the FSH and LH as well as prolactin 
levels are low due to the negative feedback mechanisms 
affecting the anterior pituitary. Boyle-Walsh et al. demon-
strated, that the glycoproteins FSH, LH and hCG in vitro 
cell culture inhibit tumour cell proliferation; in contrast, 
the proteins hPL and PRL stimulate tumour propagation. 
The changes of plasma concentration of the above men-
tioned hormones during pregnancy and their effect on 
meningioma growth are in concert with the notion, that 
regarding tumour (including meningioma) growth the 
second and third trimester are crucial and critical [23]. 
However, the pathognomonic effect of estrogen is ques-
tionable. Estrogen receptor (ER) is not expressed in the 
majority of meningiomas and this phenomenon is not dif-
ferent in the so called ‘gestational meningiomas’ [20]. It is 
interesting, that in vitro studies using reverse transcrip-
tion PCR (RT-PCR) have demonstrated that the ER expres-
sion in meningiomas is present in much higher proportion 
of cases than anticipated based on immunohistochemical 
results. These contrasting results are probably due to the 
different sensitivity of the applied techniques; however, 
the functional activity of receptors remains unknown [24]. 
The role of progesterone receptor (PR) has been studied 
in numerous papers. There is inverse relation between 
protein expression and tumour grade [25]. While the rate 
of cell division (mitosis) is increasing with higher grade, 
meningiomas in pregnancy are predominantly low grade 
(WHO I) with negligible mitotic activity. Hence, it is ques-
tionable whether the rapid tumour growth is related to 
progesterone-induced cell proliferation or not [21-22]. The 
exact role of progesterone is far from being fully eluci-
dated despite the numerous published research paper on 
this topic. Surely, the majority of meningiomas express 
PR, which can be detected also by immunohistochemis-
try [26]. The fact that tumour growth is usually occurring 
in the luteal phase of menstrual cycle or in the second or 
third trimester of pregnancy, when progesterone plasma 
concentration is higher, suggests the role of sex hormones 
in the mechanism [27]. Somewhat contradicting these 
arguments, PR is expressed not only in meningiomas of 
females but also in those of males and children; further-
more, the peak of incidence of the tumour is far beyond 
the fertile age when the serum level of progesterone is 
relatively low. The moderately increased meningioma risk 
in women diagnosed with breast cancer is in accordance 
with the higher risk of breast cancer in females who pre-
viously had meningioma, supporting the potential role of 
hormonal mechanisms in the tumour development [28]. 
Moreover, long term hormone replacement therapy also 
raises the possibility of disease, although such correlation 
has not been shown after use of oral contraceptives [29].
2.2  Possible vascular mechanisms
During pregnancy the cardiovascular system shows 
several significant physiological changes. Stroke volume 
(which is the volume of blood ejected from the left ven-
tricle per beat) from the 6th week of pregnancy till the 28th 
week is increased by 30-40%, and in parallel with these 
changes the heart rate also accelerates by 15-20/min com-
pared to the non-pregnant period. Plasma volume and 
red blood cell count increase by 40-50% and by 20-30%, 
respectively, leading to physiologic haemodilution and 
decrease of blood viscosity by 20%. Total peripheral 
resistance is reduced therefore the resting blood pres-
sure should not exceed 140/90 Hg mm. The decreasing 
albumin production of the liver together with the increas-
ing amount of total body water lead to oedema formation. 
However, PTBE can be associated with meningiomas inde-
pendently of pregnancy [11]. Primarily, it accompanies 
angiomatous and secretory meningioma subtypes [12]. 
Nassehi examined 43 patients who suffered from meningi-
oma associated with PTBE. His results showed that VEGF 
protein and mRNA levels correlate with the oedema index 
(which is calculated from the volume of tumour + PTBE 
divided by the volume of tumour). Comparing the genders, 
in women the water content was higher whereas VEGF 
protein level was lower in the tumour [30]. Another paper 
suggests that the elevated VEGF protein levels within the 
oedema are derived from the protein secretion of tumour 
and not from de novo protein synthesis of PTBE [31]. Con-
sequently, the angiogenic factor produced by the tumour 
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plays crucial role in PTBE genesis. Furthermore, the risk of 
recurrence is higher as a consequence of the extension of 
oedema [2]. As noted, the exact role of VEGF in the growth 
of gestational meningioma is not clearly understood, also 
due to the relatively low number of analyzed cases. The 
body of literature suggesting crucial role of rapid vascu-
lar changes in the mechanism is derived mainly from the 
morphological examination of tumour. Some researchers 
have identified typical foamy, swollen, oedematous cells 
in the histopathological meningioma samples resected 
from pregnant women [32]. Other studies have found that 
the presence of increased vascularity and focal patholog-
ical alterations, such as intra- or extracellular oedema, 
are significantly higher in the cases of ‘gestational men-
ingioma’, in contrast to meningiomas of non-pregnant 
women [20]. Although size of the tumour could decrease 
after child-birth, it could increase again during the next 
pregnancy; these features suggest a reversible underlying 
mechanism [18]. Rare benign vascular tumours, such as 
intracranial capillary haemangioma also mimic meningi-
oma [33]. Consequently, the hemodynamic changes with 
their reversible nature, probably play a remarkable role 
in the pathogenesis and growth of the tumour. However, 
the above mentioned alterations are not detectable in all 
pregnant women with meningioma. Furthermore, the 
rapid growth of tumour in pregnancy is not a generally 
applicable law. Bringing to light the possible role of pro-
gesterone in the regulation of brain blood vessel function 
would facilitate to understand the connection between 
endocrine mechanisms and vascular changes [34]. More 
than likely that the endocrine and vascular mechanisms 
are not acting independently, but rather both responsible 
for the altered behaviour of ‘gestational meningiomas’ 
(Table 1). 
3  Symptoms, diagnostics, therapy
Taking the tumour’s anatomical location into account, 
there is no general rule regarding clinical symptoms and 
biological behaviour. Sometimes a small meningioma 
can cause severe symptoms, whereas a large one can be 
asymptomatic for a long time. The tumour compresses the 
surrounding structures leading to complaints and clin-
ical signs. The most frequent symptoms are: headache, 
dizziness, focal lesions and epileptic fits. Skull base is a 
common localisation of meningioma, thus its accelerated 
growth during pregnancy often gives rise to visual distur-
bances [20]. Extremely large meningiomas cause rapid 
increase of intracranial pressure. The compression of optic 
nerve leads to reduced venous return, resulting in a blurry 
and oedematous papilla on funduscopy. Squeezing of the 
oculomotor nerve causes functional deficit of intraocu-
lar muscles, anisocoria, pupillary dilatation and absence 
of light reaction. Increased intracranial pressure is also 
accountable for nausea, vomitus, confusion and finally 
the patient fall into coma as a consequence of transtento-
rial herniation and brainstem compression [35]. Because 
of these unspecific symptoms, differential diagnosis from 
the other complications of pregnancy could be difficult. 
The most common conditions showing similar symptoms 
are: eclampsia, hyperemesis gravidarum and post-partum 
psychosis [36]. In the process of establishing the accurate 
diagnosis, the first step is the detailed physical exam-
ination. As next, the use of imaging techniques is also 
essential. During pregnancy, MRI is the preferred choice 
because X-ray has teratogenic effects. Therapy should be 
both timely and personalised, depending on the charac-
teristics of intracranial process, stage of pregnancy and 
general condition of foetus and mother. If possible, the 
first choice is close observation until labour [37]. Pharma-
ceutical therapy aims to reduce brain oedema and halt its 
progression. The wide use of corticosteroids against PTBE 
is not always effective. Moreover, the long-term side effects 
of the drug is not negligible. Despite VEGF inhibitors 
having remarkable pharmaceutical effect, the drugs are 
contraindicated during pregnancy due to the well-known 
severe teratogenic side effects (i.e.: phocomelia caused by 
thalidomide)[38]. Preventing epileptic seizures is a major 
goal of the therapy, in order to avoid fetal hypoxia during 
seizures. There should be special emphasis on avoidance 
and prevention of possible teratogenic effects of any med-
ications and diagnostic procedures. Mannitol adminis-
tration is not recommended except in cases of life-threat-
ening brain oedema, since it significantly decreases the 
utero-placental blood flow [39]. Although some reports 
claim that accurately calculated whole brain radiotherapy 




• Female predominance of meningiomas
• Growth mainly occurs in the 2nd and 3rd 
trimester, and in the luteal phase of 
mentruation cycle (when the progesterone
plasma level is elevated)
Reversible hemodynamical changes
Support the hypothesis
• Many swollen cells
• Increased vascularity, intra- or extracellular
edema in the tumour
• Reversibility: regression after childbirth
Against the hypothesis
• Progesterone receptor expressed in also in
meningiomas of males and children
• The peak incidence is postmenopausal
Unclear
• Link to cell proliferation
• Role of physiological vascular effects
Against the hypothesis
• Peritumoral edema occurs in meningiomas of 
non-pregnant patients
• These changes are not always detectable in 
gestational meningomas
Unclear
• Link to hormonal changes
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with special emphasis on protecting the abdominal region 
is a low-risk and effective local therapy during pregnancy 
[22], focal irradiation of the tumour is currently the pre-
ferred option in rapidly growing and malignant meningi-
omas [40]. Stereotactic radiosurgery (gamma knife) treat-
ment is also often possible, depending on tumour size 
and localization [41]. Surgical resection is still the main 
curative treatment of meningiomas, whereby the extent 
of PTBE is also reduced after a successful neurosurgical 
intervention. If the tumour is non-resectable, antipro-
gesterone (i.e. mifepristone) and chemotherapeutic (i.e. 
hydroxyurea) drugs might be considered. Urgent surgical 
intervention is usually necessary in cases of malignant 
meningioma, conventionally untreatable hydrocephalus, 
and progressively enlarging potentially life-threatening 
tumours. Brain surgery during pregnancy is extraordinar-
ily risky for both mother and child, thus the continuous 
intraoperative monitoring as well as the professional high 
quality cooperation amongst brain surgeons, obstetrician 
and anaesthesiologist are inevitable [35].
4  Conclusion
’Gestational meningioma’ is a rare but frequently 
life-threatening disease that is characterized by unusual 
behaviour compared to meningiomas of non-pregnant 
women. The detailed pathophysiology in the background 
of rapid tumour growth has not been fully understood. 
Based on available data it is suspected that endocrine and 
vascular changes play crucial roles. Diagnosis in most 
cases is possible based on clinical symptoms, physical 
examination and results obtained by modern imaging 
techniques. Taking into account the severe and some-
times lethal consequences, often only timely and effective 
therapy can save the lives of mother and foetus.
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